BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 11927285)

  • 1. Complexities in the development of cyclin-dependent kinase inhibitor drugs.
    Sausville EA
    Trends Mol Med; 2002; 8(4 Suppl):S32-7. PubMed ID: 11927285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
    Hirai H; Kawanishi N; Iwasawa Y
    Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase inhibitors: novel anticancer agents.
    Mani S; Wang C; Wu K; Francis R; Pestell R
    Expert Opin Investig Drugs; 2000 Aug; 9(8):1849-70. PubMed ID: 11060782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():471-488. PubMed ID: 30508677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
    Grant S; Roberts JD
    Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early development of cyclin dependent kinase modulators.
    Roy KK; Sausville EA
    Curr Pharm Des; 2001 Nov; 7(16):1669-87. PubMed ID: 11562305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
    Klein MA
    Adv Protein Chem Struct Biol; 2020; 121():115-141. PubMed ID: 32312419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
    Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
    Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting the "Cdk-centric" view of the mammalian cell cycle.
    Malumbres M
    Cell Cycle; 2005 Feb; 4(2):206-10. PubMed ID: 15655365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
    Kaubisch A; Schwartz GK
    Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin-dependent kinase inhibitors as anticancer drugs.
    Krystof V; Uldrijan S
    Curr Drug Targets; 2010 Mar; 11(3):291-302. PubMed ID: 20210754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and clinical development of cyclin-dependent kinase modulators.
    Senderowicz AM; Sausville EA
    J Natl Cancer Inst; 2000 Mar; 92(5):376-87. PubMed ID: 10699068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase pathways as targets for cancer treatment.
    Shapiro GI
    J Clin Oncol; 2006 Apr; 24(11):1770-83. PubMed ID: 16603719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK inhibitors in cancer therapy: what is next?
    Malumbres M; Pevarello P; Barbacid M; Bischoff JR
    Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.
    Bose P; Simmons GL; Grant S
    Expert Opin Investig Drugs; 2013 Jun; 22(6):723-38. PubMed ID: 23647051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L; Siu KT; Raje N
    Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.
    Vermeulen K; Van Bockstaele DR; Berneman ZN
    Cell Prolif; 2003 Jun; 36(3):131-49. PubMed ID: 12814430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase inhibitors for treating cancer.
    Toogood PL
    Med Res Rev; 2001 Nov; 21(6):487-98. PubMed ID: 11607930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
    Chou J; Quigley DA; Robinson TM; Feng FY; Ashworth A
    Cancer Discov; 2020 Mar; 10(3):351-370. PubMed ID: 32071145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.